
Guggenheim lowered the firm’s price target on C4 Therapeutics (CCCC) to $6 from $7 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CCCC | C4 Therapeutics | 2.48 | 0.04 | 1.64% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.48 | +1.64% |

Guggenheim lowered the firm’s price target on C4 Therapeutics (CCCC) to $6 from $7 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source

Reports Q3 revenue $8.47M, consensus $8.52M. “Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment landscape while advancing

Lake Street initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and $11 price target Management describes cemsidomide as the most potent and selective IKZF1/3 degrader in its class

JPMorgan initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $10 price target The firm cites the potential of the company’s lead asset cemsidomide in multiple myeloma for

C4 Therapeutics ( ($CCCC) ) has issued an announcement. On September 25, 2026, C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and Phase

C4 Therapeutics (CCCC) presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma, RRMM, in a poster presentation

Reports Q2 revenue $6.64M, consensus $4M. “The first half of 2026 was a period of execution for cemsidomide, our next-generation IKZF1/3 degrader, and our clinical development plan. At the EHA

C4 Therapeutics, Inc. (CCCC) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street analysts expect C4 Therapeutics, Inc. to post earnings of -$0.23 per share.

An update from C4 Therapeutics ( ($CCCC) ) is now available. On June 24, 2026, C4 Therapeutics, Inc. held its Annual Meeting of Stockholders, at which shareholders elected Andrew J.

C4 Therapeutics (CCCC) will present further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $320.41M | $-0.21 | $5.52M | 0.09 | -3.39 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.